A systematic review and meta-analysis of the evidence base for add-on treatment for patients with major depressive disorder who have not responded to antidepressant treatment: A European perspective

Journal of Psychopharmacology

Volumn 28, Issue 2, 2014, Pages 85-98

  Turner, Pauline ^a   Kantaria, Rakesh ^a   Young, Allan H ^b  

^a ASTRAZENECA   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Add on treatment; atypical antipsychotic; augmentation; Europe; inadequate response; major depressive disorder; systematic review

Indexed keywords

ANTIDEPRESSANT AGENT; LITHIUM; MIRTAZAPINE; PLACEBO; QUETIAPINE; S ADENOSYLMETHIONINE;

ADD ON THERAPY; COMPARATIVE EFFECTIVENESS; DEPRESSION; DRUG EFFICACY; DRUG RESPONSE; EUROPE; EVIDENCE BASED PRACTICE; HUMAN; META ANALYSIS; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SYSTEMATIC REVIEW;

ADD-ON TREATMENT; ATYPICAL ANTIPSYCHOTIC; AUGMENTATION; EUROPE; INADEQUATE RESPONSE; MAJOR DEPRESSIVE DISORDER; SYSTEMATIC REVIEW;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; HUMANS;

EID: 84892917722     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881113507640     Document Type: Review

References (37)

1. Alvarez E, Vinas F. Mirtazapine in combination. Actas Esp Psiquiatr. 2010 ; 38: 121-128
2. Anderson IM, Ferrier IN, Baldwin RC, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2008 ; 22: 343-396 (Pubitemid 351989984)
3. Bauer M, Adli M, Bschor T, et al. Lithium's emerging role in the treatment of refractory major depressive episodes: Augmentation of antidepressants. Neuropsychobiology. 2010 ; 62: 36-42
4. Bauer M, Bschor T, Pfennig A, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care. World J Biol Psychiatry. 2007 ; 8: 67-104 (Pubitemid 46690921)
5. Bauer M, Pretorius HW, Constant EL, et al. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: Results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry. 2009 ; 70: 540-549
6. Birnbaum HG, Kessler RC, Kelley D, et al. Employer burden of mild, moderate, and severe major depressive disorder: Mental health services utilization and costs, and work performance. Depress Anxiety. 2010 ; 27: 78-89
7. Bostwick JM, Pankratz VS. Affective disorders and suicide risk: A reexamination. Am J Psychiatry. 2000 ; 157: 1925-1932
8. Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997 ; 50: 683-691 (Pubitemid 27341818)
9. Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry. 2002 ; 51: 183-188 (Pubitemid 34127908)
10. Chisholm A. Exploring UK attitudes towards unlicensed medicines use: A questionnaire-based study of members of the general public and physicians. Int J Gen Med. 2012 ; 5: 27-40
11. Chisholm D, Diehr P, Knapp M, et al. Depression status, medical comorbidity and resource costs. Evidence from an international study of major depression in primary care (LIDO). Br J Psychiatry. 2003 ; 183: 121-131 (Pubitemid 36963137)
12. Cochrane Collaboration (2011) Cochrane Handbook for Systematic Reviews of Interventions Available at: http://www.cochrane-handbook.org/ (accessed 9 August 2012).
13. Connolly KR, Thase ME. If at first you don't succeed: A review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs. 2011 ; 71: 43-64
14. Cusin C, Yang H, Yeung A, et al Handbook of Clinical Rating Scales and Assessment in Psychiatry and Mental Health. Baert L Blais M, ed. New York, NY: Humana Press, pp ; 2010: 7-37.
15. Daly EJ, Trivedi MH, Wisniewski SR, et al. Health-related quality of life in depression: A STAR*D report. Ann Clin Psychiatry. 2010 ; 22: 43-55
16. Edwards SJ, Clarke MJ, Wordsworth S, et al. Indirect comparisons of treatments based on systematic reviews of randomised controlled trials. Int J Clin Pract. 2009 ; 63: 841-854
17. El-Khalili N, Joyce M, Atkinson S, et al. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: A multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2010 ; 13: 917-932
18. European Medicines Agency. Central Authorisation of Medicines. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/about-us/general/general- content-000109.jsp&mid=WC0b01ac0580028a47&jsenabled=true (accessed 6 June 2012).
19. Fleurence R, Williamson R, Jing Y, et al. A systematic review of augmentation strategies for patients with major depressive disorder. Psychopharmacol Bull. 2009 ; 42: 57-90
20. General Medical Council (2008) Good Practice in Prescribing Medicines. Available at: http://www.gmc-uk.org/static/documents/content/Good-Practice-in- Prescribing-Medicines-0911.pdf (accessed 9 August 2012).
21. Judd LL, Paulus MJ, Schettler PJ, et al. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness?. Am J Psychiatry. 2000 ; 157: 1501-1504
22. Knoth RL, Bolge SC, Kim E, et al. Effect of inadequate response to treatment in patients with depression. Am J Manag Care. 2010 ; 16: e188 - e196
23. Licht RW, Qvitzau S. Treatment strategies in patients with major depression not responding to first-line sertraline treatment. A randomised study of extended duration of treatment, dose increase or mianserin augmentation. Psychopharmacology (Berl). 2002 ; 161: 143-151 (Pubitemid 34492659)
24. Masand PS, Gupta S. Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine. Ann Clin Psychiatry. 2002 ; 14: 175-182 (Pubitemid 36172566)
25. Morris DW, Budhwar N, Husain M, et al. Depression treatment in patients with general medical conditions: Results from the CO-MED trial. Ann Fam Med. 2012 ; 10: 23-33
26. National Institute for Health and Clinical Excellence (2009) Depression: the treatment and management of depression in adults (National Clinical Practice Guideline 90). Available at: http://www.nice.org.uk/nicemedia/pdf/Depression- Update-FULL-GUIDELINE.pdf (accessed 1 July, 2013).
27. Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: A meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009 ; 166: 980-991
28. Nierenberg AA, Papakostas GI, Petersen T, et al. Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants. J Clin Psychopharmacol. 2003 ; 23: 92-95 (Pubitemid 36164430)
29. Papakostas GI, Mischoulon D, Shyu I, et al. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: A double-blind, randomized clinical trial. Am J Psychiatry. 2010 ; 167: 942-948
30. Rush AJ. Limitations in efficacy of antidepressant monotherapy. J Clin Psychiatry. 2007 ; 68: 8-10 (Pubitemid 47507831)
31. Rush AJ, Trivedi MH, Stewart JW, et al. Combining Medications to Enhance Depression Outcomes (CO-MED): Acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry. 2011 ; 168: 689-701
32. Schulz KF, Chalmers I, Hayes RJ, et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995 ; 273: 408-412
33. Sobocki P, Jonsson B, Angst J, et al. Cost of depression in Europe. J Ment Health Policy Econ. 2006 ; 9: 87-98 (Pubitemid 44018376)
34. Song F, Altman DG, Glenny AM, et al. Validity of indirect comparison for estimating efficacy of competing interventions: Empirical evidence from published meta-analyses. BMJ. 2003 ; 326: 472
35. Spielmans GI, Berman MI, Linardatos E, et al. Adjunctive atypical antipsychotic treatment for major depressive disorder: A meta-analysis of depression, quality of life, and safety outcomes. PLoS Med. 2013 ; 10: e1001403
36. Stein G, Bernadt M. Lithium augmentation therapy in tricyclic-resistant depression. A controlled trial using lithium in low and normal doses. Br J Psychiatry. 1993 ; 162: 634-640 (Pubitemid 23150996)
37. Wittchen HU, Jacobi F, Rehm J, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011 ; 21: 655-679